Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo

Science Translational Medicine

Volumn 8, Issue 325, 2016, Pages

  Ashton, Susan ^a   Song, Young Ho ^b   Nolan, Jim ^b   Cadogan, Elaine ^a   Murray, Jim ^a   Odedra, Rajesh ^a   Foster, John ^a   Hall, Peter A ^a   Low, Susan ^b   Taylor, Paula ^a   Ellston, Rebecca ^a   Polanska, Urszula M ^a   Wilson, Joanne ^a   Howes, Colin ^a   Smith, Aaron ^a   Goodwin, Richard J A ^a   Swales, John G ^a   Strittmatter, Nicole ^c   Takáts, Zoltán ^c   Nilsson, Anna ^d   Andren, Per ^d   Trueman, Dawn ^a   Walker, Mike ^a   Reimer, Corinne L ^a   Troiano, Greg ^b   Parsons, Donald ^b   De Witt, David ^b   Ashford, Marianne ^a   Hrkach, Jeff ^b   Zale, Stephen ^b   Jewsbury, Philip J ^a   Barry, Simon T ^a   more..

^a ASTRAZENECA   (United Kingdom)

^b BIND Therapeutics   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 [3 [[7 [3 [ETHYL(2 HYDROXYETHYL)AMINO]PROPOXY]QUINAZOLIN4 YL]AMINO] 1H PYRAZOL 5 YL] N (3 FLUOROPHENYL)ACETAMIDE; ACCURIN POLYMERIC NANOPARTICLE; AURORA KINASE INHIBITOR; BARASERTIB; NANOPARTICLE; UNCLASSIFIED DRUG; 2-((3-((4-((5-(2-((3-FLUOROPHENYL)AMINO)-2-OXOETHYL)-1H-PYRAZOL-3-YL)AMINO)QUINAZOLIN-7-YL)OXY)PROPYL)(ETHYL)AMINO)ETHYL DIHYDROGEN PHOSPHATE; AURORA KINASE; ORGANOPHOSPHATE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG RETENTION; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; MOLECULARLY TARGETED THERAPY; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE MARROW; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; FEMALE; MASS SPECTROMETRY; METABOLISM; MOUSE; NUDE RAT; PATHOLOGY; SCID MOUSE; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; AURORA KINASES; BONE MARROW; CELL LINE, TUMOR; DRUG LIBERATION; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MICE; MICE, SCID; NANOPARTICLES; ORGANOPHOSPHATES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RATS, NUDE; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84958632643     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aad2355     Document Type: Article

References (27)

1. G. Pillai, Nanomedicines for cancer therapy: An update of FDA approved and those under various stages of development. SOJ Pharm. Pharm. Sci. 1, 13 (2014).
2. A. Z. Wang, R. Langer, O. C. Farokhzad, Nanoparticle delivery of cancer drugs. Annu. Rev. Med. 63, 185-198 (2012).
3. A. M. Rahman, S. W. Yusuf, M. S. Ewer, Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int. J. Nanomedicine 2, 567-583 (2007).
4. M. N. Kundranda, J. Niu, Albumin-bound paclitaxel in solid tumors: Clinical development and future directions. Drug Des. Devel. Ther. 9, 3767-3777 (2015).
5. J. Hrkach, D. Von Hoff, M. Mukkaram Ali, E. Andrianova, J. Auer, T. Campbell, D. DeWitt, M. Figa, M. Figueiredo, A. Horhota, S. Low, K. McDonnell, E. Peeke, B. Retnarajan, A. Sabnis, E. Schnipper, J. J. Song, Y. H. Song, J. Summa, D. Tompsett, G. Troiano, T. Van Geen Hoven, J. Wright, P. LoRusso, P. W. Kantoff, N. H. Bander, C. Sweeney, O. C. Farokhzad, R. Langer, S. Zale, Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med. 4, 128ra139 (2012).
6. A. V. Kalra, J. Kim, S. G. Klinz, N. Paz, J. Cain, D. C. Drummond, U. B. Nielsen, J. B. Fitzgerald, Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion. Cancer Res. 74, 7003-7013 (2014).
7. M. Kollareddy, D. Zheleva, P. Dzubak, P. S. Brahmkshatriya, M. Lepsik, M. Hajduch, Aurora kinase inhibitors: Progress towards the clinic. Invest. New Drugs 30, 2411-2432 (2012).
8. S. R. Park, M. Davis, J. H. Doroshow, S. Kummar, Safety and feasibility of targeted agent combinations in solid tumours. Nat. Rev. Clin. Oncol. 10, 154-168 (2013).
9. C. Ditchfield, V. L. Johnson, A. Tighe, R. Ellston, C. Haworth, T. Johnson, A. Mortlock, N. Keen, S. S. Taylor, Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J. Cell Biol. 161, 267-280 (2003).
10. C. Ditchfield, N. Keen, S. S. Taylor, The Ipl1/Aurora kinase family: Methods of inhibition and functional analysis in mammalian cells. Methods Mol. Biol. 296, 371-381 (2005).
11. R. W. Wilkinson, R. Odedra, S. P. Heaton, S. R. Wedge, N. J. Keen, C. Crafter, J. R. Foster, M. C. Brady, A. Bigley, E. Brown, K. F. Byth, N. C. Barrass, K. E. Mundt, K. M. Foote, N. M. Heron, F. H. Jung, A. A. Mortlock, F. T. Boyle, S. Green, AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin. Cancer Res. 13, 3682-3688 (2007).
12. D. S. Boss, P. O. Witteveen, J. van der Sar, M. P. Lolkema, E. E. Voest, P. K. Stockman, O. Ataman, D. Wilson, S. Das, J. H. Schellens, Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann. Oncol. 22, 431-437 (2011).
13. H. M. Kantarjian, G. Martinelli, E. J. Jabbour, A. Quintás-Cardama, K. Ando, J.-O. Bay, A. Wei, S. Gröpper, C. Papayannidis, K. Owen, L. Pike, N. Schmitt, P. K. Stockman, A. Giagounidis; SPARK-AML1 Investigators, Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer 119, 2611-2619 (2013).
14. E. Komlodi-Pasztor, D. L. Sackett, A. T. Fojo, Inhibitors targeting mitosis: Tales of how great drugs against a promising target were brought down by a flawed rationale. Clin. Cancer Res. 18, 51-63 (2012).
15. K. Avgoustakis, Pegylated poly (lactide) and poly (lactide-co-glycolide) nanoparticles: Preparation, properties and possible applications in drug delivery. Curr. Drug Deliv. 1, 321-333 (2004).
16. A. A. Mortlock, K. M. Foote, N. M. Heron, F. H. Jung, G. Pasquet, J.-J. M. Lohmann, N. Warin, F. Renaud, C. De Savi, N. J. Roberts, T. Johnson, C. B. Dousson, G. B. Hill, D. Perkins, G. Hatter, R. W. Wilkinson, S. R. Wedge, S. P. Heaton, R. Odedra, N. J. Keen, C. Crafter, E. Brown, K. Thompson, S. Brightwell, L. Khatri, M. C. Brady, S. Kearney, D. McKillop, S. Rhead, T. Parry, S. Green, Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J. Med. Chem. 50, 2213-2224 (2007).
17. L. E. Friberg, M. Sandström, M. O. Karlsson, Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model. Invest. New Drugs 28, 744-753 (2010).
18. R. Wilkinson, R. Odedra, S. Heaton, S. Wedge, N. Keen, J. Foster, M. Waker, J. Young, K. Foote, M. Brady, The Aurora B kinase inhibitor AZD1152 demonstrates potent antitumor efficacy in preclinical models using a range of dosing routes and schedules. Cancer Res. 67, 4358-4358 (2007).
19. N. Keen, S. Taylor, Aurora-kinase inhibitors as anticancer agents. Nat. Rev. Cancer 4, 927-936 (2004).
20. G. P. Collins, T. A. Eyre, K. M. Linton, J. Radford, G. D. Vallance, E. Soilleux, C. Hatton, A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma. Brit. J. Haematol. 170, 886-890 (2015).
21. H. M. Kantarjian, M. A. Sekeres, V. Ribrag, P. Rousselot, G. Garcia-Manero, E. J. Jabbour, K. Owen, P. K. Stockman, S. D. Oliver, Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML. Clin. Lymphoma Myeloma Leuk. 13, 559-567 (2013).
22. R. Gaudana, A. Parenky, R. Vaishya, S. K. Samanta, A. K. Mitra, Development and characterization of nanoparticulate formulation of a water soluble prodrug of dexamethasone by HIP complexation. J. Microencapsul. 28, 10-20 (2011).
23. N. M. Pinkerton, A. Grandeury, A. Fisch, J. Brozio, B. U. Riebesehl, R. K. Prud'homme, Formation of stable nanocarriers by in situ ion pairing during block-copolymer-directed rapid precipitation. Mol. Pharm. 10, 319-328 (2013).
24. L. Cadzow, M. L. Lam, Y.-H. Song, M. Figueiredo, H. Wang, D. DeWitt, V. Pucci, J.-R. Mo, E. Lewis-Clark, H. Ferguson, M. Gindy, S. Low, S. Zale, J. Hrkach, C. McGregor, B. J. Long, Accurins improve the pharmacokinetics, pharmacodynamics, tolerability and anti-tumor activity of the AKT inhibitor MK-2206, Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, 2015, abstract C197.
25. N. Keen, S. Taylor, Mitotic drivers-Inhibitors of the Aurora B kinase. Cancer Metastasis Rev. 28, 185-195 (2009).
26. K. E. Hook, S. J. Garza, M. E. Lira, K. A. Ching, N. V. Lee, J. Cao, J. Yuan, J. Ye, M. Ozeck, S. T. Shi, X. Zheng, P. A. Rejto, J. L. Kan, J. G. Christensen, A. Pavlicek, An integrated genomic approach to identify predictive biomarkers of response to the Aurora kinase inhibitor PF-03814735. Mol. Cancer Ther. 11, 710-719 (2012).
27. A. Saad, M. Palm, S. Widell, S. Reiland, Differential analysis of rat bone marrow by flow cytometry. Comp. Haematol. Int. 10, 97-101 (2000).